CD38 and neoplasm: By FCM analyses, tumor cells stained with GFP and anti-human CD45 of both PBMC (10.28% vs. 1.50%) and bone marrow cells (BMC) (52.63% vs. 0.04%) were significantly reduced in mice treated with BCMA-CD38 CAR-T cells, compared with those treated with T cells on d36.